JEVTANA® (cabazitaxel): Potential for medication error in the preparation of Jevtana®

Sanofi-Aventis would like to inform healthcare professionals of the potential for medication error in the preparation of Jevtana® (cabazitaxel). Cases of reconstitution errors were reported in the European Union with Jevtana®, leading to overdose, with an actual dose delivered that was 15% to 20% higher than the prescribed dose. Investigations revealed that there was lack of clarity in the product information where information on the overfills in Jevtana concentrate vial and the solvent vial (to compensate for liquid loss during preparation) was not clearly mentioned. Healthcare professionals are advised to refer to the Dear Healthcare Professional Letter which explains the existence and purpose of the overfills for both Jevtana concentrate and solvent vials as well the appropriate preparation instructions for the infusion solution of Jevtana®.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.